Clinical trials: Rejection
Renal Transplant Rejection
Deep Phenotyping of the Renal Allograft to Prognosticate Clinical Outcomes
The goal of this observational study is to determine phenotypic, transcriptional, and epigenetic underpinnings of renal allograft rejection in renal transplant rejection.
- Trial name
- NCT06438107
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Pittsburgh
Prevention of Acute Rejection After Kidney Transplantation
Clinical Study to Evaluate the Tolerability, Safety and Efficacy of Enteric-coated Mycophenolate Sodium, After Equimolar Conversion From Mycophenolate Mofetil (MMF), in Patients With Stable Renal Transplant Receiving Tacrolimus
The aim of the study is to assess the safety and efficacy of enteric-coated mycophenolate sodium, given in combination with tacrolimus, after equimolar dose conversion from MMF to enteric-coated mycophenolate sodium in stable…
- Trial name
- NCT00171392
- Testing
- Enteric-coated mycophenolate sodium
- Volunteers
- 132 people
- Sponsor
- Novartis
Kidney Diseases
Mycophenolate Mofetil (MMF): A Long-Term Data Evaluation
The purposes of this study are: To review past clinical use of mycophenolate mofetil (MMF) in kidney transplant patients; To discover why doses were modified and how those modifications affected the survival and health of the…
- Trial name
- NCT00203671
- Volunteers
- 651 people
- Sponsor
- University of California, Los Angeles
Liver Transplant Failure and Rejection
Parenteral Ascorbic Acid Repletion in TransplantatIon
A single-center, randomized, double-blinded placebo-controlled trial is proposed to investigate administration of supraphysiologic doses of ascorbic acid (vitamin C, AA) to patients undergoing liver transplantation.
- Trial name
- PARTI (NCT04756063)
- Testing
- Ascorbic acid
- Where
- United States
- Sponsor
- University of Wisconsin, Madison
Brain Death, Organ Donation
Goal of Open Lung Ventilation in Donors
The primary goal of this study is to assess whether ventilation of deceased organ donors with an open lung protective ventilatory strategy will improve donor lung utilization rates and donor oxygenation compared to a conventional…
- Conditions
- Brain Death, Organ Donation, Organ Transplant Failure or Rejection
- Trial name
- GOLD (NCT03439995)
- Testing
- Open lung protective ventilation, Conventional ventilation
- Where
- 4 sites in United States
- Volunteers
- 154 people
- Sponsor
- Vanderbilt University Medical Center
Lung Transplant Rejection
Longitudinal Study of Cell Free DNA in Lung Transplant
Lung transplant is a viable treatment strategy for many with end-stage lung diseases. Despite advances in both the surgical and medical management, lung transplant recipients experience episodes of allograft insult and injury…
- Trial name
- LoSt (NCT04234919)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Colorado, Denver
Evidence of Liver Transplantation
Reduction of Tacrolimus Dose in Association With Mycophenolate Mofetil After Liver Transplantation
The prevention of graft rejection after liver transplantation benefits nowadays from a variety of newly developed immunosuppressive agents.
- Trial name
- MMF-FK (NCT00151632)
- Testing
- Mycophenolate mofetil, Tacrolimus
- Where
- 8 sites in France
- Volunteers
- 195 people
- Sponsor
- Rennes University Hospital
Graft Rejection, Heart Diseases
IMAGE: A Comparison of AlloMap Molecular Testing and Traditional Biopsy-based Surveillance for Heart Transplant Rejection
This study is designed to evaluate the safety and efficacy of a leukocyte gene expression profiling method in the monitoring of asymptomatic heart transplant patients for acute rejection.
- Trial name
- NCT00351559
- Testing
- AlloMap molecular expression testing, Right ventricular endomyocardial biopsy
- Where
- 13 sites in United States
- Volunteers
- 629 people
- Sponsor
- XDx
End-Stage Renal Disease, End Stage Renal Disease on Dialysis
CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk
This clinical trial investigates the transplantation of donor kidneys that have been genetically modified ex vivo using CRISPR-Cas9 genome editing to reduce immunogenicity and transplant rejection.
- Conditions
- End-Stage Renal Disease, End Stage Renal Disease on Dialysis, End Stage Renal Disease With Renal Transplant, Kidney Transplant Rejection
- Trial name
- NCT07053462
- Testing
- Ex Vivo CRISPR-Cas9 Gene Editing of Donor Kidney, Kidney Transplantation with Standard Care
- Where
- China
- Volunteers
- 90 people
- Sponsor
- AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC
Kidney Transplant
Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Crossmatch Deceased Donor Kidney Transplant
The purpose of this study is to test whether a dosing regimen of eculizumab in addition to standard posttransplant care in positive crossmatch deceased donor kidney transplant recipients will reduce the incidence of acute humoral…
- Trial name
- NCT01106027
- Testing
- Eculizumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Mayo Clinic
Heart-lung Transplant Rejection
Assessment of Revascularization Versus Conservative Treatment in Heart Transplant Patients for a Clinical Event Reduction
The aim of the study is to compare optimal medical therapy alone versus percutaneous coronary intervention on top of medical therapy in the setting of heart transplant recipient coronary artery disease in a randomized trial.The…
- Trial name
- ARCHER (NCT01795729)
- Testing
- Stent, optimal medical therapy
- Where
- France
- Volunteers
- 6 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Antibody-mediated Rejection, Kidney Tranplant
The Safety and Efficacy of CD38 Monoclonal Antibody Monotherapy for CaAMR in Renal Transplantation
Renal transplantation is the best choice for the treatment of end-stage renal disease, but the long-term survival of the graft is still remains a challenge.
- Trial name
- NCT05913596
- Testing
- Daratumumab
- Where
- China
- Volunteers
- 15 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Renal Transplant Recipients
Calcineurin Inhibitor-Free Immunosuppression in Renal Transplant Recipients at Low Immunogenic Risk
To compare renal function (51Cr-EDTA clearance) 12 months posttransplant, in primary renal allograft recipients (from cadaveric donor) at low immunogenic risk, 0 DR mis-match, receiving immunosuppressive therapy with A) Zenapax®…
- Trial name
- NCT00138970
- Testing
- Zenapax®, CellCept® and prednisolone, Sandimmun Neoral®, CellCept® and prednisolone
- Volunteers
- 70 people
- Sponsor
- University of Oslo School of Pharmacy
Renal Function, Liver Transplant
Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
This study was designed to assess the evolution of renal function and to collect efficacy, safety, and tolerability data of everolimus in co-exposure with reduced CNI in paediatric liver transplant recipients.
- Trial name
- NCT01598987
- Testing
- Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation.
- Where
- 32 sites in United States, Australia and 10 more
- Volunteers
- 56 people
- Sponsor
- Novartis Pharmaceuticals
Heart Transplantation
SCHEDULE Follow Up Visit 5-7 yr
The major aim of this extension study was to evaluate the long-term effect (i.e. 5 to 7 years) of early initiation of everolimus and early elimination of CsA compared to standard immunosuppressive regimen including CsA on primary…
- Trial name
- CRAD001ANO05 (NCT02864706)
- Testing
- Everolimus, Cyclosporine, Mycophenolate mofetil
- Where
- 6 sites in Denmark, Norway and 1 more
- Volunteers
- 95 people
- Sponsor
- Novartis Pharmaceuticals
Graft Rejection
Safety/Efficacy of Everolimus and Neoral® in Adult Cardiac Transplant Patients With Established Allograft Vasculopathy
Everolimus is an immunosuppressive drug that is being studied for preventing acute rejection that can happen after heart transplantation. It is usually used in combination with other immunosuppressive drugs such as cyclosporine.
- Trial name
- NCT00097968
- Testing
- everolimus
- Where
- 6 sites in United States
- Sponsor
- Novartis Pharmaceuticals
Renal Transplant Rejection
The Effect of Rituximab on the Development of Anti-Donor Antibodies
The aim of the study is to find out if Rituximab, which is an antibody against specific white cells involved in rejection, when combined with standard anti-rejection treatment can more effectively reverse the rejection process.
- Trial name
- NCT00695097
- Testing
- Rituximab, No Rituximab
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- University of California, San Francisco
Viruria, Viremia
An Open-Label, Study to Treat Patients With Renal Allograft and Polyoma BK Viruria
This study will evaluate the clinical efficacy and safety of a combination of leflunomide and orotic acid in kidney transplant patients with high levels of Polyoma BK viruria for the purpose of preventing Polyoma BK viremia and…
- Trial name
- NCT01620268
- Testing
- Leflunomide and orotic acid
- Where
- 9 sites in United States
- Volunteers
- 24 people
- Sponsor
- Changzheng-Cinkate
Liver Failure, Liver Failure, Acute
Use of N-Acetylcysteine During Liver Procurement
Randomized prospective study on the impact on the post-LT outcome by the infusion of N-acetylcysteine (NAC) during the liver procurement procedure, as an anti-oxidant agent to reduce the ischemia-reperfusion damage of organs for…
- Conditions
- Liver Failure, Liver Failure, Acute, Liver Diseases, Carcinoma, Hepatocellular
- Trial name
- NCT01394497
- Testing
- N-acetylcystein
- Where
- Italy
- Volunteers
- 140 people
- Sponsor
- Azienda Ospedaliera di Padova
Graft Rejection, Kidney Failure
Study Comparing Two Sirolimus Regimens vs. Tacrolimus and Mycophenolate Mofetil Regimen in Kidney Transplant Recipients
To demonstrate the superiority of SRL + TAC elimination + corticosteroids (Group I) and SRL + MMF + corticosteroids (Group II) to TAC + MMF + corticosteroids (Group III) with respect to renal allograft function at month 12…
- Conditions
- Graft Rejection, Kidney Failure, Kidney Transplant
- Trial name
- NCT00266123
- Testing
- Sirolimus
- Volunteers
- 420 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer